

**ALKEM LABORATORIES LTD.**

**Regd. Office :** ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: [contact@alkem.com](mailto:contact@alkem.com) • Website: [www.alkemlabs.com](http://www.alkemlabs.com)
- CIN: L00305MH1973PLC174201

29<sup>th</sup> June, 2026

To,

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	--

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)-  
Updates on Acquisition.**

Dear Sir(s)/ Madam,

This is in continuation of our earlier intimations dated 13<sup>th</sup> February, 2026 and 06<sup>th</sup> March, 2026, wherein the Stock Exchanges were informed that M/s. Alkem Medtech Private Limited, a wholly owned subsidiary of the Company in India (“Alkem Medtech”), intends to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG (“Occlutech”), a company incorporated in Switzerland and had executed Share Purchase Agreement with inter alia the selling shareholders of Occlutech respectively.

In this regard, we wish to inform you that on 26<sup>th</sup> June, 2026, Alkem Medtech has executed First Supplementary Agreement to Share Purchase Agreement dated 6<sup>th</sup> March, 2026 with inter alia the selling shareholders of Occlutech.

A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,  
For **Alkem Laboratories Limited**

**Manish Narang**  
**President – Legal, Company Secretary & Compliance Officer**

Encl: a/a